^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MUC4 (Mucin 4, Cell Surface Associated)

    i
    Other names: MUC4, Mucin 4, Cell Surface Associated, Pancreatic Adenocarcinoma Mucin, Mucin 4, Tracheobronchial, Ascites Sialoglycoprotein, Tracheobronchial Mucin, Testis Mucin, ASGP
    10d
    Low-Grade Fibromyxoid Sarcoma and Related Subtypes: A Systematic Review and Pooled Analysis of 773 Cases. (PubMed, Cancers (Basel))
    LGFMS exhibits indolent histology but potential for late recurrence and metastasis, warranting prolonged radiological follow-up and multicenter studies to evaluate adjuvant strategies.
    Retrospective data • Review • Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    23d
    Clinical trial of safety, tolerability and preliminary efficacy of crept-618 combined with tirelizumab injection in the treatment of unresectable hepatocellular carcinoma (ChiCTR2600117700)
    P=N/A, N=10, Not yet recruiting, People's Hospital of Deyang City; People's Hospital of Deyang City
    New trial
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    Tevimbra (tislelizumab-jsgr)
    23d
    Bile duct tumor thrombus (intraductal polypoid growth)-positive intrahepatic cholangiocarcinoma: clinicopathologic and genomic analysis. (PubMed, J Pathol)
    These results highlight the importance of evaluating BDTT in SDT, as it may be the main route of hilar extension in aggressive cases.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • BAP1 (BRCA1 Associated Protein 1) • KMT2D (Lysine Methyltransferase 2D) • MUC1 (Mucin 1) • SMAD4 (SMAD family member 4) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • MUC4 (Mucin 4, Cell Surface Associated) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2) • RSPO3 (R-Spondin 3) • CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A) • MUC17 (Mucin 17) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6) • PTPRK (Protein Tyrosine Phosphatase Receptor Type K) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR2 rearrangement
    24d
    Novel Case of a Molecularly Confirmed Low-Grade Fibromyxoid Sarcoma of the Floor of the Mouth and Literature Review. (PubMed, Head Neck Pathol)
    This case highlights the critical role of molecular testing in the diagnosis of LGFMS and emphasizes the importance of appropriate management strategies, including aggressive local control and long-term surveillance, given the tumor's risk of late recurrence and distant metastasis.
    Review • Journal
    |
    FUS (FUS RNA Binding Protein) • MUC4 (Mucin 4, Cell Surface Associated)
    25d
    Preclinical evaluation of gefitinib and betulin-loaded surface functionalized liposomes for the treatment of hepatocellular carcinoma via asialoglycoprotein receptor targeting. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Western blotting and immunohistochemistry (IHC) showed that both GEF-BET-Lipo and GEF-BET-Lf-Lipo treatments significantly reduced pSTAT3 expression and increased the levels of the apoptotic marker caspase-3. Overall, the findings support the enhanced antitumor potential of GEF-BET-Lf-Lipo against HCC in animals.
    Preclinical • Journal
    |
    CASP3 (Caspase 3) • MUC4 (Mucin 4, Cell Surface Associated)
    |
    gefitinib
    28d
    Immunohistochemical Analysis of MUC1 and MUC4 Co-expression in Oral Leukoplakia and Oral Squamous Cell Carcinoma. (PubMed, Ann Afr Med)
    The findings suggest that MUC1 and MUC4 are significantly overexpressed in OSCC compared to OL, and their co-expression may serve as a valuable biomarker combination for early diagnosis and prognosis. Elevated expression of both mucins is associated with poor prognosis, indicating their potential for use in clinical practice for risk stratification and personalized treatment in OSCC patients.
    Journal
    |
    MUC1 (Mucin 1) • MUC4 (Mucin 4, Cell Surface Associated)
    1m
    A Phase I Study of CREPT-618 in Locally Advanced HCC (clinicaltrials.gov)
    P1, N=13, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    2ms
    An update on the diagnostic and prognostic value of mucin 4 in gastric cancers. (PubMed, Expert Rev Mol Diagn)
    MUC4 expression in gastric cancer is associated with disease aggressiveness, lymphatic invasion, and nodal metastasis. Due to its role in disease pathobiology, it is a promising target for the diagnosis and therapy of gastric cancer.
    Review • Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    2ms
    Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy. (PubMed, J Gastroenterol Hepatol)
    Furthermore, CTCs provide a platform for companion diagnostics by reflecting mutational and resistance profiles, particularly in the context of targeted therapies and immune checkpoint inhibitors. Despite current limitations in standardization, sensitivity, and scalability, the integration of CTC analysis into clinical practice holds potential to enhance precision medicine strategies in HCC.
    Review • Journal • Circulating tumor cells • Liquid biopsy • IO Companion diagnostic • IO biomarker
    |
    AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • MUC4 (Mucin 4, Cell Surface Associated) • THY1 (Thy-1 membrane glycoprotein)
    2ms
    Acral Mesenchymal Spindle Cell Neoplasm With a Novel HMGA2::NCOA2 Fusion. (PubMed, J Cutan Pathol)
    As the first known case to date with this fusion, these findings contribute to the emerging research on genomic testing in acral soft tissue tumors. Additional cases and longer clinical follow-up are needed to better characterize the novel HMGA2::NCOA2 fusion.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CD34 (CD34 molecule) • SOX10 (SRY-Box 10) • MUC4 (Mucin 4, Cell Surface Associated) • HMGA2 (High mobility group AT-hook 2) • TP63 (Tumor protein 63) • NCOA2 (Nuclear Receptor Coactivator 2) • SLC2A1 (Solute Carrier Family 2 Member 1)
    2ms
    Dual Inhibition of KRAS G12D and PI3K/BRD4 Signaling Overcomes Therapeutic Resistance in Pancreatic Cancer. (PubMed, Acta Biomater)
    When combined with the KRAS G12D inhibitor MRTX1133, MDP5 resensitized resistant cancer cells. This combination synergistically enhanced apoptosis and proliferation inhibition, outperforming the standard-of-care, Gemcitabine (GEM)...Mechanistically, dual inhibition suppresses AKT/YAP signaling, depletes CD44+/ALDH+ cells, and shifts the tumor immune milieu (↑CD8a, ↑CD86, ↓Ly-6G). By integrating molecular targeting with multi-pathway blockade, this work addresses two major barriers-resistance and delivery-and outlines a generalizable strategy to improve precision nano therapy for KRAS-mutant pancreatic cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1) • MUC4 (Mucin 4, Cell Surface Associated) • BRD4 (Bromodomain Containing 4) • CD86 (CD86 Molecule)
    |
    KRAS mutation • KRAS G12D
    |
    gemcitabine • MRTX1133
    2ms
    Chitosan-Based Drug Delivery Systems for Targeted Chemotherapy in Colorectal Cancer: A Scoping Review. (PubMed, Mar Drugs)
    Moreover, no clinical trials currently assess CS-based nanocarriers for the treatment of CRC. Overall, CS represents a promising modular platform for targeted nanomedicine, but translational progress requires bridging preclinical success with comprehensive in vivo and clinical evaluation.
    Review • Journal
    |
    FOLR1 ( Folate receptor alpha ) • MUC4 (Mucin 4, Cell Surface Associated)